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Abstract
Background: FcRc is an immunoreceptor tyrosine-based activation motif (ITAM)-signalling protein essential for
immunoreceptor signaling and monocyte, macrophage and NK cell function. Previous study from our laboratory showed
that FcRc is down-regulated in HIV-infected macrophages in vitro. FcRc expression in immune cells present in HIV-infected
individuals is unknown.
Methodology/Principal Findings: We compared FcRc expression in peripheral blood mononuclear cells isolated from HIV-
1-infected individuals receiving combination antiretroviral therapy and healthy, HIV-1-uninfected individuals. FcRc mRNA
and protein levels were measured using quantitative real-time PCR and immunoblotting, respectively. CD56
+ CD94
+
lymphocytes isolated from blood of HIV-1 infected individuals had reduced FcRc protein expression compared to HIV-
uninfected individuals (decrease=76.8%, n=18 and n=12 respectively, p=0.0036). In a second group of patients, highly
purified NK cells had reduced FcRc protein expression compared to uninfected controls (decrease=50.2%, n=9 and n=8
respectively, p=0.021). Decreased FcRc expression in CD56+CD94+ lymphocytes was associated with reduced mRNA
(51.7%, p=0.021) but this was not observed for the smaller group of patients analysed for NK cell expression (p=0.36).
Conclusion/Significance: These data suggest biochemical defects in ITAM-dependent signalling within NK cells in HIV-
infected individuals which is present in the context of treatment with combination antiretroviral therapy.
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Introduction
HIV-1 infection, like other chronic inflammatory diseases, is
associated with immune activation, which is an important
independent predictor of HIV-1 disease progression [1,2].
Immune activation may be caused by a combination of persistent
HIV-1 replication and innate immune activation via gut-
associated pathogens, associated with loss of gut-associated
lymphoid tissue (GALT) [3] Immune activation markers on
leukocytes and in plasma may persist even after initiation of
combination antiretroviral therapy (cART) [4,5,6]. The observa-
tion that GALT is not as rapidly restored as peripheral blood CD4
T cell counts following cART [7,8] suggests that immune
activation due to elevated bacterial products and its downstream
consequences also persist after viral suppression, which is indicated
by elevated endotoxin levels in plasma even after 48 weeks of
cART [3].
Chronic inflammatory diseases are characterised by defective
immunoreceptor signaling mediated by immunoreceptor tyrosine-
based activation motif (ITAM) domain-containing adaptor
proteins (reviewed in [9]). The only reports of ITAM protein
expression in the context of HIV infection have been older
observations that HIV-1 infection in patients not receiving cART
was associated with decreased expression of TCRf (an ITAM-
signalling protein that mediates T-cell receptor signaling) in
bystander cells that are not necessarily infected by HIV-1,
including NK and CD8
+ T cells [10,11,12]. Limited data suggest
that expression of TCRf is restored by cART [10].
Fc receptor common c-chain (FcRc) is the most widespread
ITAM-signaling protein. It is broadly expressed in haematopoietic
cells including monocytes, macrophages, NK cells and effector
CD4
+ T cells. It is promiscuously associated with, and transduces
signals from, a broad range of immunoreceptors, including FcaR,
FceR, FccR, NKp46 and TCR [13]. Studies using NK cells from
FcRc knockout mice show that this protein is absolutely required
for NK cell mediated cytotoxicity [14]. We have previously shown
that FcRc expression is decreased in human monocyte-derived
macrophages (MDM) infected with HIV-1 in vitro, leading to
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macrophages [15,16]. This inhibition is not restricted to HIV-1-
infected cells [16] suggesting that HIV-1 infection reduces FcRc
expression by a bystander mechanism. Whether HIV reduces
FcRc in other cell types is not known. There have been no studies
examining expression of FcRc in chronic inflammatory diseases,
and in the context of HIV-1 infection in particular. Given the
importance of FcRc in signaling from a wide variety of
immunoreceptors, and our in vitro observations that HIV-1
infection causes a bystander-mediated decrease in FcRc expres-
sion, we examined its expression in peripheral blood mononuclear
cells from a cohort of HIV-1 infected patients receiving cART.
Methods
Ethics Statement
This study is approved by The Alfred Human Research Ethics
Committee (Project 36/02) with a protocol that conforms to the
provisions of the Declaration of Helsinki (as revised in Edinburgh
2000).
Objectives
To measure FcRc expression in peripheral blood cells from a
current cohort of HIV-infected and control, HIV-uninfected
subjects. We hypothesise that HIV-infection is associated with
decreased expression of FcRc in the context of treatment with
combination antiretroviral therapy (cART).
Participants
All HIV-infected individuals were recruited from the Alfred
Hospital Infectious Diseases Outpatient Clinic (Melbourne,
Australia) and were receiving cART with no history of, or current,
AIDS-defining illness at recruitment. Blood samples were collected
by venepuncture into EDTA containing blood collection tubes
with informed written consent. Gender-matched, healthy HIV-
uninfected individuals were recruited via advertisement within the
Burnet Institute (Melbourne, Australia) and blood was collected
with ethics approval and written informed consent by venepunc-
ture into EDTA tubes.
Antibodies
Mouse anti-GAPDH mAb (clone 6C5) was from Santa Cruz
Biotechnology, and rabbit anti-FcRc antiserum was from Dr.
Bruce Wines (Burnet Institute, Melbourne, Australia). Mouse
fluorochrome-conjugated antibodies CD3-FITC, CD14-PE,
CD14-FITC, CD16-PerCP-Cy5.5, CD19-FITC, CD56-APC,
CD94-APC and isotype matched IgG1-FITC, -PE, -PerCP-
Cy5.5 and -APC were from BD Biosciences. Goat anti-rabbit
Alexa FluorH 680 and goat anti-mouse IRDye
TM 800 were from
Molecular Probes and Rockland Immunochemicals, respectively.
Cell Isolation
Peripheral blood mononuclear cells (PBMC) were labeled with
25 mg/ml anti-CD3-FITC and anti-CD14-PE, or 37.5 mg/ml of
anti-CD56-APC and anti-CD94-APC or with corresponding
mouse IgG1 isotype control antibodies. Cells were washed twice
in cold FACS sorting buffer (Ca
2+,Mg
2+ free PBS, 2 mM EDTA,
1% newborn calf serum (HyClone)) and resuspended at
4610
7 cells/ml. CD14
+ monocytes, CD3
2 CD56
+/CD94
+ NK
cells, and CD3
+ T lymphocytes were isolated using a high-speed
cell sorter (FACSAria
TM, BD Biosciences) under PC3 containment
conditions. In selected experiments, PBMC were stained with
25 mg/ml each of anti-CD3-FITC, anti-CD14-FITC and anti-
CD19-FITC, 37.5 mg/ml of each anti-CD16-PerCP-Cy5.5 and
anti-CD56-APC in combination. NK cells (gated on CD3
2/
CD14
2/CD19
2 cells in the lymphocyte region) were subsequently
sorted into CD56
dim CD16
+ and CD56
bright CD16
2 subsets.
Sorted cells were washed twice in cold Ca
2+,Mg
2+-free PBS, and
10
5 cells from each population were lysed with RNA lysis/binding
buffer [16]. Remaining cells were lysed with 200 ml cold Triton
lysis buffer (TLB) [16]. TLB extracts were incubated at 4uC for
10 min and clarified at 20,0006g for 10 min at 4uC.
Measurement of FcRc and TCRf mRNA Expression
FcRc mRNA was measured by quantitative real-time PCR (Q-
PCR) as described [16]. TCRf (GenBank accession NM198053)
mRNA was measured under identical conditions but using the
forward primer 59-TCAGCCTCTGCCTCCCAGCCTCTTTCT-
39 and reverse primer 59-CTCACTGTAGGCCTCCGCCA-39.
Both FcRc and TCRf mRNA levels were quantified using the
comparative threshold method, with GAPDH mRNA as internal
standard. FcRc was co-immunoprecipitated from cellular extracts
with GAPDH as an internal control then immunoprecipitates were
resolved by SDS PAGE. Blots were probed with rabbit anti-FcRc
plus mouse anti-GAPDH then goat anti-rabbit Alexa FluorH 680 plus
goat anti-mouse IRDye
TM 800. Fluorescence in both channels was
quantified using a LI-COR Odyssey infrared (IR) imager (LI-COR
Biosciences) and expressed as a ratio of FcRc:GAPDH fluorescence.
Statistical Analysis
Statistical significance between uninfected and HIV-1-infected
groups was calculated using Mann-Whitney non-parametric U
test. Spearman’s rank test for non-parametric data was used to
determine correlations. All statistical analyses were carried out
using Prism 5.0 software (GraphPad Software). Significance was
assumed when probability values were ,0.05.
Results
RNA extracts prepared from a single HIV-uninfected donor
were analysed by PCR. FcRc mRNA was expressed at high levels
in monocytes and moderate levels in NK cells, but low levels in T
lymphocytes (Figure 1A–C). Within CD56/CD94-positive cells
most of the expression was found within CD3
2 NK cells and only
minor expression within the CD3
+ population. TCRf was not
detected in monocytes (Figure 1B,C). Protein analysis also showed
a lack of FcRc expression in T lymphocytes either within the
whole CD3
+ population or specifically within CD56
+/CD94
+ T
lymphocytes (Figure 1C). FcRc mRNA expression was similar in
both the CD56
brightCD162 and CD56
dimCD16+NK subsets
(Figure 1D,E). In the following experiments, FcRc expression
was therefore measured in monocyte and NK cell lysates and
TCRf expression in T cell and NK cell lysates.
Monocytes and T lymphocytes were purified from blood
sampled from eighteen HIV-infected patients (subjects 1–18,
Table 1) and twelve healthy, HIV-uninfected individuals. All
patients received cART at time of recruitment and most (78%)
had viral load (VL),50 copies/ml. Monocytes from HIV-infected
individuals showed a small but significant increase in FcRc mRNA
(median HIV+=23.30, HIV2=17.10, p=0.037, Figure 2A)
compared to that from uninfected controls, although similar levels
of FcRc protein were expressed (median HIV+=6.155,
HIV2=6.465, p=0.88, Figure 2B). TCRf mRNA expression
in T lymphocytes was unchanged in these patients (median
HIV+=3.95, HIV2=5.60, p=0.21, Figure 3A) consistent with
previous findings that TCRf expression is restored following
cART [10]. Analysis of CD56
+/CD94
+ cells from the sorted
populations (consisting of NK cells plus CD56
+/CD94
+ lympho-
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HIV+=10.9, HIV2=12.1, p=0.74, Figure 3B).
When FcRc expression was compared, however, the CD56
+/
CD94
+ cell population showed a considerable decrease in both
FcRc mRNA expression (median HIV+=7.2, HIV2=14.9,
p=0.021, Figure 4A) and protein expression (median
HIV+=1.040, HIV2=4.490, p=0.0036, Figure 4B). Since
within this mixed population only the CD3
2CD56
+/CD94
+ NK
cell fraction expressed appreciable FcRc (Figure 1B,C) this
suggests that decreased FcRc expression in HIV-infected individ-
uals occurs in NK cells. To address this, a further nine HIV-
infected patients (subjects 19–27, Table 1) and eight control
subjects were enrolled and PBMC prepared from these individuals
were specifically sorted to obtain highly purified monocytes and
NK cells. There was a 50% decrease in FcRc protein expression
(median protein HIV+=2.061, HIV2=4.139, p=0.021,
Figure 5A) but FcRc mRNA expression was unchanged (median
RNA HIV+=20.30, HIV2=26.30, p=0.36, Figure 5B) in NK
cells from HIV-infected individuals. Levels of TCRf mRNA in
NK cells were equivalent in the two populations (median mRNA
HIV+=8.80, HIV2=17.35, p=0.34, Figure 5C) again consis-
tent with previous reports [10]. There was no significant
correlation between decreased FcRc protein levels in NK cells
with either nadir or current CD4 counts (r=20.22, p=0.58 and
r=0.18, p=0.64 respectively) from these HIV-1-infected individ-
uals (n=9, patients 19–27). Since only one patient (patient 22,
Table 1) had high level of viremia, determining whether levels of
FcRc correlated with viral load was not possible. However since
five of the nine patients examined had an undetectable viral load,
it is not likely that viremia is a significant contributor to reduced
NK cell FcRc expression in the context of HIV infection.
Chronic HIV-1 infection is associated with a progressive decline
in NK cell numbers and function [17]. We therefore examined the
potential association between FcRc expression and NK cell
proportion in peripheral blood mononuclear cells. Unexpectedly,
there was a strong negative correlation between FcRc protein
levels and the proportion of NK cells in HIV-infected individuals
(Spearman’s r=20.71, p=0.037, Figure 6A) although the
proportion of NK cells was not significantly different in this
cohort of cART treated patients compared to uninfected control
subjects (Figure 6B) in agreement with results from others [18].
Similarly, we observed a negative correlation between FcRc
mRNA concentration and proportion of NK cells in these
individuals (r
2=0.52, p=0.028, data not shown). There was no
Figure 1. FcRc and TCRf expression in human peripheral blood mononuclear cell populations. (A). Monocytes (CD3
2 CD14
+ cells, ii),
CD3
2/+ CD56
+/CD94
+ cells (a mixture of CD56
+/CD94
+ T lymphocytes and NK cells, iii), T lymphocytes (CD3
+ cells, ii) and pure NK cells and CD56
+/
CD94
+ T lymphocytes (CD3
2 CD56
+/CD94
+ cells, and CD3
+ CD56
+/CD94
+ cells respectively, iv) were isolated from PBMC (i) of an HIV-negative donor,
by FACS to .97% purity for each population (v-ix). (B) FcRc, TCRf and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA levels were
measured by conventional PCR using serial 10-fold dilutions of cell extract as indicated. (C). FcRc expression was measured by immunoblotting in
protein extracts from the indicated cell populations purified by FACS. (D). Lymphocytes were initially gated from PBMC of a healthy, HIV-uninfected
donor using light scatter properties (i) then NK cells gated as CD3
2 CD14
2 CD19
2 cells (ii). Gates were established for NK cell subsets
(CD56
brightCD162 and CD56
dimCD16+, (iii)) which were then sorted by FACS to 99.0% and 95.1% purity respectively (iv and v). (E). FcRc and GAPDH
mRNA expression in each NK cell subset were determined by conventional PCR using serial 10-fold dilutions of cell extract as indicated.
doi:10.1371/journal.pone.0009643.g001
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Donor CD4 (cells/ml) Nadir CD4 (cells/ml) Viral load (RNA copies/ml) Current therapy regimen
1
1 640 40 8300 3TC, TDF, ATV, T20,
2 396 143 ,50 FTC, TDF, FPV
3 57 54 6750 3TC, ABC, FPV
4 599 50 ,50 3TC, AZT, ATV
5 178 140 ,50 FTC, TDF, NVP,
6 381 0 1600 DRV, ETV, 3TC, RTV
7 243 72 .100,000 3TC, D4T, TDF, DRV, T20
8 830 110 ,50 3TC, ABC, LPV
9 352 54 ,50 3TC, ABC, ATV
10 430 0 ,50 FTC, TDF, LPV
11 598 230 ,50 FTC, TDF, RGV, T20
12 728 231 ,50 3TC, ABC,NVP
13 365 258 ,50 FTC, TDF, EFV
14 381 381 ,50 3TC, ABC, NVP
15 891 315 ,50 3TC, AZT, NVP
16 639 252 ,50 FTC, TDF, NVP,
17 1205 308 ,50 FTC, TDF, EFV
18 1176 230 ,50 FTC, TDF, NVP
19 255 149 ,50 3TC, TDF, NVP
20 275 67 1700 FTC, TDF, EFV
21 720 97 ,50 3TC, TDF, NVP
22 15 15 .100,000 AZT, ABC, 3TC, ETV, RGV
23 179 139 900 TDF, ABC, 3TC, ETV, RGV
24 703 100 ,50 FTC, TDF, NVP
25 250 89 350 TDF, FTC, NVP
26 802 376 ,50 AZT, 3TC, NVP
27 172 40 ,50 AZT, 3TC, NVP
13TC: lamivudine, ABC: abacavir, ATV: atazanavir, AZT: zidovudine, D4T: stavudine, DRV: darunavir, EFV: efavirenz, ETV: etravirine, FPV: fosamprenavir, FTC: emtricitabine,
LPV: lopinavir, NVP: nevirapine, RGV: raltegravir, RTV: ritonavir, T20: enfuvirtide, TDF: tenofovir.
doi:10.1371/journal.pone.0009643.t001
Figure 2. FcRc expression in monocytes of HIV-infected and uninfected individuals. FcRc mRNA (A) and protein (B) were determined by Q-
PCR and quantitative infrared immunoblotting in extracts from monocytes purified by FACS from blood of HIV-1 infected (individuals 1–18, Table 1)
and control subjects. Fluorescence from FcRc immunoblots measured at 680 nm was normalised to fluorescence of GAPDH in the same
immunoblots, measured at 800 nm. FcRc mRNA was determined from real-time PCR measurements using the comparative threshold method with
GAPDH mRNA serving as internal control. Differences between groups were tested using the Mann-Whitney U test for non-parametric data, with a
value ,0.05 assumed to be significant. Horizontal bars represent median values.
doi:10.1371/journal.pone.0009643.g002
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HIV-uninfected subjects at both mRNA and protein levels
(r
2=5 610
25, p=0.99 and r
2=0.024, p=0.71, respectively). In
this group of patients, therefore, decreased FcRc expression is
principally found in HIV-1-infected individuals with preserved
NK cell numbers. It is not likely that decreased FcRc expression is
due to a shift in the proportion of CD56
dim CD16
+ NK and
CD56
bright CD16
2 cell subsets since both subsets express similar
levels of FcRc (Figure 1E).
Discussion
We have shown that FcRc mRNA and protein expression in
HIV-infected individuals receiving cART is decreased in CD56
+/
CD94
+ lymphocytes in which the major FcRc-expressing cells are
NK cells, but are not decreased in monocytes. We confirmed that
the decrease occurs in NK cells using cells purified from a second
group of patients also receiving cART. Decreased FcRc expression
was due to loss of FcRc expression at a single cell level, and not
due to depletion of FcRc-expressing NK cells, or altered
proportions of NK cell subsets within the CD56
+/CD94
+
population of our cohort of HIV-infected individuals. FcRc
protein expression within monocytes is not altered, suggesting that
the defect in ITAM protein expression is specific for FcRc in NK
cells. This is also suggested by the observation that TCRf mRNA
levels were not decreased in either T lymphocytes or NK cells
purified from these individuals. This is the first report of expression
of the important ITAM signalling protein FcRc in peripheral
blood mononuclear cells from patients with HIV-1 infection or, to
our knowledge, any viral infection.
Since FcRc expression in human immune cells is not well
documented, it was initially measured in monocytes, T lympho-
cytes and CD56
+/CD94
+ lymphocytes obtained from uninfected
individuals and showed high levels of expression of both mRNA
and protein in monocytes and CD56
+/CD94
+ lymphocytes.
Within the CD56
+/CD94
+ lymphocytes population, FcRc was
only detected in NK cells but not in CD56/CD94-expressing T
lymphocytes (Figure 1). This observation suggests that FcRc
Figure 4. FcRc expression in CD56
+/CD94
+ lymphocytes of HIV-infected and uninfected individuals. FcRc mRNA (A) and protein (B) were
measured in FACS-sorted CD56
+/CD94
+ lymphocytes from blood of HIV-1 infected (individuals 1–18, Table 1) and control subjects by Q-PCR using the
comparative threshold and quantitative immunoblotting method as described. The Mann-Whitney U test was used to assess statistical significance.
Horizontal bars represent median values.
doi:10.1371/journal.pone.0009643.g004
Figure 3. TCRf expression in CD56+/CD94+ and CD3+ T lymphocyte populations of HIV-infected and uninfected individuals. TCRf
mRNA in T lymphocytes (A) and CD56
+/CD94
+ lymphocytes (B) purified by FACS from blood of HIV-1 infected (individuals 1–18, Table 1) and control
subjects was measured by Q-PCR using the comparative threshold method as in Figure 2A. The Mann-Whitney U test was used to assess statistical
significance. Horizontal bars represent median values.
doi:10.1371/journal.pone.0009643.g003
FcRc in HIV-1 Infection
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+/CD94
+ lymphocytes was due to
FcRc-expressing NK cells. Given that FcRc also acts as a
chaperone and is required for CD16 surface expression
[19,20,21,22], the levels of FcRc in CD56
dim CD16
+ and
CD56
bright CD16
2 NK cell subsets were compared. FcRc mRNA
expression in CD56
dim CD16
+ and CD56
bright CD16
2 NK cell
subsets were however similar, which suggests that FcRc levels are
not limiting CD16 surface expression in the latter population. To
our knowledge, this is the first study to investigate FcRc expression
in NK cell subsets. Our data also show that there is little or no
FcRc expression in T lymphocytes compared to monocytes and
CD56
+/CD94
+ lymphocytes in either HIV-1-infected or unin-
fected individuals (data not shown).
In a limited number of patients, we observed an increase in
FcRc mRNA expression in monocytes relative to HIV-uninfected
subjects. This was not observed however with FcRc protein levels,
which were similar to those of uninfected individuals. The
significance of increased FcRc mRNA levels in monocytes from
HIV-1-infected individuals is unclear and will need to be
confirmed in a larger cohort of patients. In contrast to monocytes,
we observed a significant decrease in FcRc mRNA and protein
expression in CD56
+/CD94
+ lymphocytes of HIV-infected
individuals. Our data demonstrate that decreased FcRc mRNA
expression was strongly and significantly correlated with decreased
FcRc protein expression within the mixed CD56
+/CD94
+
lymphocyte population isolated from HIV-1-infected individuals.
We did not observe any significant correlation of defective FcRc
mRNA and protein with nadir or current CD4 counts. This
contrasts with the previous reports on the effect of HIV-1 infection
on TCRf expression in patients not receiving cART in which
there was a correlation with CD4 counts and an inverse
correlation with viral loads [10,11,23]. Since only NK cells within
this population express FcRc, we considered whether FcRc
depletion within CD56
+/CD94
+ lymphocytes may be caused by
the loss of FcRc-expressing NK cells. However, there was no
correlation between decreased FcRc mRNA or protein levels and
the proportion of NK cells within the sorted CD56
+/CD94
+
populations analysed (data not shown). This shows that decreased
FcRc levels in CD56
+/CD94
+ population is more likely due to loss
of FcRc expression within NK cells. We confirmed this by
measuring FcRc expression in purified NK cells from additional
patients and control subjects. FcRc mRNA levels were not
significantly decreased in NK cells from these additional patients.
When we investigated the expression of FcRc as a function of age
within the HIV-uninfected donors there was no correlation at
either the protein (r
2=0.055, p=0.34) or the mRNA level
(r
2=0.015, p=0.63). The difference between in FcRc expression
between HIV-infected and uninfected subjects is therefore not due
to differences in age. Analysis of NK cells from a larger numbers of
patients is required to determine whether decreased FcRc mRNA
Figure 5. FcRc and TCRf expression in NK cells of HIV-infected and uninfected individuals. NK cells purified from blood of an additional 9
HIV-infected (individuals 19–27, Table 1) and 8 control subjects. FcRc protein (A) and mRNA (B) and TCRf mRNA (C) were measured in FACS-sorted
CD3
2 CD56
+/CD94
+ NK cells using quantitative immunoblotting and Q-PCR as described. The Mann-Whitney U test was used to assess statistical
significance. Horizontal bars represent median values.
doi:10.1371/journal.pone.0009643.g005
Figure 6. Correlation of NK cell proportions with FcRc
expression in HIV-infected individuals. (A) Correlation between
NK cell FcRc protein expression and the proportion of NK cells in
patient PBMC (donors 19–27) measured by flow cytometry. (B)
Proportion of NK cells in PBMC (individuals 19–27, Table 1) measured
by flow cytometry. The Mann-Whitney U test was used to assess
statistical significance. Horizontal bars represent median values.
doi:10.1371/journal.pone.0009643.g006
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addressing this.
Several studies have shown that the proportion of NK cell
subsets is altered during chronic HIV-1 infection, with loss of
CD56
+ CD16
2/+ NK cells and accumulation of functionally
anergic CD56
2 CD16
+ NK cell subsets [17,24,25,26]. However,
in HIV-1 infection where viral replication is well-controlled, the
proportion of these subsets is similar to that of uninfected
individuals [17,24]. Since the majority of HIV-1-infected individ-
uals in our cohort had undetectable viral loads and we show that
both CD56
dim CD16
+ and CD56
bright CD16
2 NK cells expressed
equal levels of FcRc, alterations in the proportion of these subsets
are unlikely to account for the FcRc depletion observed in our
study. Taking all of these observations together, our results
indicate that decreased FcRc levels are likely to be due to loss of
FcRc expression within FcRc-expressing NK cells.
The potential mechanisms underlying defective FcRc transcrip-
tion within NK cells are unclear, as FcRc transcriptional
regulation is poorly understood. Recently however, Juang and
colleagues reported that Elf-1, a member of the Ets family of
transcription factors, is a negative transcriptional regulator of
FcRc in human T lymphocytes whereas it is a positive
transcriptional regulator for TCRf in the same cells [27,28].
Neither the role of Elf-1 in FcRc expression in NK cells nor the
effect of HIV-1 infection on Elf-1 expression is known. Given the
reciprocal effects of Elf-1 on FcRc and TCRf expresion, and since
we did not observe increased TCRf expression in both CD56
+/
CD94
+ lymphocytes and NK cells, we consider this an unlikely
mechanism for decreased FcRc expression.
A limitation of this study is the lack of patients with detectable
viremia to enable a correlation of FcRc expression with viral load
to be performed. This was due, in part, to the difficulty in isolating
sufficient NK cells from HIV patients with high viral loads to allow
biochemical analysis of FcRc protein levels. This is due to the low
numbers of NK cells in such individuals [17]. Firstly, although the
sample size was small, the decrease in FcRc expression in NK cells
attained statistical significance and was observed in two groups of
patients in CD56
+/CD94
+ lymphocytes and in highly purified NK
cells. This highlights the reproducible nature of the observed
decrease of FcRc expression even in patients with undetectable
viral load. The cross-sectional study described herein needs to be
extended with a longitudinal study to determine the relationship
between cART and restoration of TCRf expression in T cells and
NK cells, and the effect of cART on FcRc expression in
monocytes and NK cells.
The reason why FcRc expression decreases in NK cells but not
monocytes is not clear. Neither cell type is infected by HIV-1 to an
appreciable extent, and changes in FcRc expression reflect a
bystander mechanism. A possible explanation is that NK cells
respond more than monocytes to a soluble factor, such as a
cytokine, responsible for these changes. We have demonstrated
that HIV-1-infection of monocyte-derived macrophages in vitro
leads to defective FccR-mediated phagocytosis through a bystand-
er mechanism which was associated with FcRc protein depletion
[16]. Therefore it is of interest to investigate soluble factors that
mediate FcRc suppression in NK cells, such as TGF-b1 [29,30].
Alternatively, if changes in FcRc expression are due to persistent
immune activation it would be relevant to correlate loss of FcRc
with plasma endotoxin levels and markers of immune activation
such as HLA-DR and CD38 expression.
Our finding that FcRc is reduced in chronically-infected HIV-
infected persons receiving cART suggests that ITAM signalling
and function of the NK cell population is defective in the setting of
treatment with cART. It is known that elevated plasma endotoxin
levels and immune activation are not fully normalised by cART,
therefore it is possible that these are linked to aberrant NK cell
ITAM signalling and function.
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